Exhibit 99.1

2 © 2026, Iovance Biotherapeutics, Inc. Forward - Looking Statements Certain matters discussed in this presentation are “forward - looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in som e c ases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may, ” “ can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward - looking statements. Forward - looking st atements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future development s, and other factors believed to be appropriate. Forward - looking statements in this presentation are made as of the date of this presentation, and we undertake no duty to update or r evi se any such statements, whether as a result of new information, future events or otherwise. Forward - looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be mat erially different from those expressed in or implied by these forward - looking statements. Important factors that could cause actual results, developments, and business decisions to dif fer materially from forward - looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including ou r m ost recent Annual Report on Form 10 - K and Quarterly Reports on Form 10 - Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties i nherent in our business: the risks related to our ability to successfully commercialize our products; the acceptance by the market of our products and product candidates, if approved, an d t heir potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product ca ndi dates; the risk regarding our ability to manufacture our therapies at our Iovance Cell Therapy Center facility, including the risk that our ability to increase manufacturing capacity at our facility may adve rs ely affect our commercial launch; the risks related to our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not becom e p rofitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our pr odu ct candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with regulatory authorities may support registrational studies and subsequent approvals by reg ulatory authorities, including the risk that any of our planned registrational trials may not support approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials o r c ohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our int erpretation of the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authoriti es; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of a ut horization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of authorized treatment centers, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geo pol itical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in th is presentation assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recogn iti on policies; no new business development transactions not completed as of the period covered by this presentation; and no material fluctuation in exchange rates.

3 © 2026, Iovance Biotherapeutics, Inc. Global Leader in Innovating, Developing and Delivering TIL Therapy for Patients with Cancer 3 Approved Products Commercial Launch Financials ~100 Treatment Centers as of 10/05/26 2 >95% © 2026, Iovance Biotherapeutics, Inc. *The midpoint represents an increase of $55 million, or ~15%, over the previous guidance range of $350 to $370 million. 1. Excludes depreciation and amortization 2. Cash, cash equivalents, short - term investments, and restricted cash as of June 30, 2026. ~ 2 ,000 Patients treated with commercial and clinical Iovance TIL products U.S., Canada & Australia Multiple Markets Globally 56% Addressable Patients within 200 miles of an ATC Margin from Cost of Sales 1 Cash Runway into 2H28 2 ~$304M 2Q26 revenue >10% above 2Q26 guidance ~$99M Full Year 2026 Revenue Guidance* $410M — $420M

4 © 2026, Iovance Biotherapeutics, Inc. The Pioneer in One - Time Cell Therapy for Solid Tumors 4 4 © 2026, Iovance Biotherapeutics, Inc. 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre - Treated Patient Population; 2. Karapetyan L et al. Transplantat ion & Cell Therapy 2026. Physician - assessed confirmed ORR by RECIST v1.1. All evaluable patients received commercial Amtagvi acc ording to the U.S. prescribing information; 3. Ahn MJ et al. J Clin Onc 2024;43:260 - 272. 4. Interim data cut as of October 10, 2025 of patients with nonsquamous NSCLC with minimum cell dose based on FDA feedback for melanoma. Patien ts progressed on or after chemotherapy and anti - PD - 1 therapy for mNSCLC without EGFR, ROS1 or ALK genomic mutations and received at least one line of FDA - approved targeted therapy if indicated by other action able tumor mutations; 5. Cash, cash equivalents, short - term investments, and restricted cash as of June 30, 2026 ; 6. Excludes depreciation and amortization *Nonsquamous mNSCLC without EGFR, ROS1 or ALK genomic mutations Abbreviations: 2L, second line; COS, cost of sales; FTD, fast track designation; mDOR, median duration of response; mNSCLC, metastatic non - small cell lung cancer; OpEx , operating expenses; ORR, objective response rate; mOS, median overall survival; SOC, standard of care Platform Technology and Robust Pipeline in Blockbuster Solid Tumor Indications Operational Excellence Focused on Profitability ~7X U.S. Melanoma Opportunity in 2L mNSCLC * $1B+ U.S. Sales Potential in 2L+ Advanced Melanoma • ~$304M cash, with runway into second half 2028 5 • ~56% gross margin from COS in 2Q26 and 50% YTD 6 • Ongoing initiatives improving OpEx , cost of sales and gross margin • Leading IO pipeline in solid tumors • Internal manufacturing • 5K+ annual capacity for North America, Europe & APAC • ~2K commercial & clinical infusions • High unmet need with limited treatment options • SOC: 12.8% ORR; 5.6 months mDOR; 12.3 months mOS 3 • Potential best - in - class lifileucel clinical profile: 25.6% ORR; mDOR not reached at 25.4 months follow up 4 • FTD for NSCLC from U.S. FDA • Potential launch in 2H27 • Leverages melanoma commercial footprint and manufacturing • First and only approved treatment in 2L+ advanced melanoma • ~66% YoY revenue growth in 2Q26 • 2Q26 revenue >10% above 2Q26 guidance • 5 - year durability : 31.4% ORR; 19.7% OS; mDOR of 36.5 months 1 • Real - world ~44% ORR ; 52% ORR in patients with ≤ 2 prior lines of therapy 2

5 © 2026, Iovance Biotherapeutics, Inc. Strong Platform Supports Backbone IO Therapy for Solid Tumors Iovance Retains Global Portfolio and Technology Platform Rights Abbreviations: 2L, second line; 4L, fourth line; CRC, colorectal cancer; DDLPS, dedifferentiated liposarcoma; ER, estrogen - recep tor; FTD, Fast Track Designation; IO, immuno - oncology; HNSCC, head and neck squamous cell carcinoma; IL - 2, interleukin 2; IL - 12, interleukin 12; NSCLC, non - small cell lung cancer; PD - 1, programmed cell death prote in - 1; TNBC, triple negative breast cancer; UPS, undifferentiated pleomorphic sarcoma Approved Amtagvi Treatment Regimen Canada EU Australia Switzerland (1H 2027) UK (2H 2026) U.S. Additional Clinical & Commercial Use Under Review Pending PHASE 3 PHASE 2 PHASE 1 INDICATION & TREATMENT SETTING TILVANCE - 301 (FTD, Confirmatory) Frontline advanced melanoma Lifileucel + pembrolizumab Amtagvi Label Expansion IOV - LUN - 202 (FTD) Post - chemo & anti - PD - 1 advanced NSCLC Lifileucel SARATOGA (FTD) Post - chemo advanced soft tissue sarcomas (DDLPS or UPS) Lifileucel IOV - END - 201 Post - chemo & anti - PD - 1 endometrial cancer Lifileucel IOV - GM1 - 201 Post anti - PD - 1 advanced melanoma or NSCLC IOV - 4001 (PD - 1 Inactivated TIL) Next - Generation Products IOV - IL2 - 101 TIL treatment regimen IOV - 3001 (IL - 2 analog) IOV - GE1 - 201 Post - ICI CRC, TNBC/ER Low, HNSCC, NSCLC IOV - 5001 (IL - 12 tethered TIL)

7 © 2026, Iovance Biotherapeutics, Inc. Significant Unmet Need in Frontline and Beyond 1 Advanced Melanoma Market Opportunity 2L+ Advanced Melanoma Population 2,3 US: 8.5K Potential ex - US Markets: 22 K Overall (1L+): 7 0K BRAF wild - type (prior ICI therapy ) ~ 5 months BRAF mutated (prior ICI and targeted therapy) ~ 3 months 1. Chesney J, et al. J Immunother Cancer. 2022; 2. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2026 Estimates. https:/ /s eer.cancer.gov (accessed June 2026); World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022;3. Data on file as of August 2026. Includes more than 20,000 patients initial target markets plus additional po ten tial markets; 4. Larkin J, Chiarion - Sileni V, Gonzalez R, et al. NEJM. 5. Robert C, et al.; Lancet 6. Tawbi HA, Schadendorf D, Lipson EJ, et al. NEJM 7. Patrinely JR et al.Cancer.2020 Abbreviations: 1L, first line; ICI, immune checkpoint inhibitors; mOS, median overall survival; mPFS, median progression - free su rvival; PD - (L)1, programmed death receptor - 1 or programmed death - ligand >50% of patients on 1L standard of care progress within 12 months 4 - 6 mOS after Progression on 1L Therapy: 7

8 © 2026, Iovance Biotherapeutics, Inc. One Third of Responses Remain Ongoing without Subsequent Treatment 5 - Year OS 19.7% mDOR 36.5 Months ORR 31.4% mOS 13.9 Months 1. Medina et al, ASCO 2025. Pooled Analysis (n=153), Heavily Pre - Treated Patient Population Abbreviations: mDOR, median duration of response; mOS, median overall survival; NR, not reached; ORR, objective response rate Duration of Response Overall Survival Deep and Durable Responses at 5 - Year Follow Up 1 Median Follow Up 57.8 Months

9 © 2026, Iovance Biotherapeutics, Inc. 52 % ORR (12/23) OS Not Reached Best - in - class real - world data driving increased Amtagvi adoption 1 1. Karapetyan L et al. Transplantation & Cell Therapy 2026 2. Three Prior Lines of Therapy (1L - 3L): 1L ipilimumab + nivolumab; 2L dabrafenib + trametinib; 3L nivolumab + relatlimab. 86% r eduction in target lesions. Response ongoing at 260 - day follow up. Photo Credit and Permission: H. Lee Moffitt Cancer Center 3. For more information, please visit https://www.iovance.com/scientific - publications - presentations/ Abbreviations: DCR, disease control rate; ORR, objective response rate 44 % ORR (18/41) 33% ORR (6/18) Before Lifileucel Post - Lifileucel (Week 6) Durable Ongoing Partial Response (PR) 2 Significant tumor burden reduction at Week 6 ≤ 2 prior lines of therapy ≥ 3 prior lines of therapy Unprecedented Real - World Response Rates of >50% ORR in multiple studies 3 73% DCR ( 30/41) Higher Respon se Rates with Earlier Treatment

10 © 2026, Iovance Biotherapeutics, Inc. One Shared Infrastructure with Scalable Expansion Melanoma Medical Oncologist Currently Treating NSCLC Medical Oncologist Educating Sarcoma Medical Oncologist Educating Endometrial Medical Oncologist Educating One - Time Treatment 1 1 Patient Identification 2 2 Tumor Tissue Procurement 3 3 Centralized Manufacturing 4 4 Administration Existing Institutional Groundwork Supports Label Expansion Surgeons Tumor Tissue Procurement · Trained once, serve every indication Cell Therapists Authorized Treatment Centers · Trained once, serve every indication

11 © 2026, Iovance Biotherapeutics, Inc. • The only scaled, centralized FDA - approved commercial TIL manufacturing process • Continually improving end - to - end commercial turnaround (~31 days) • Modular design • 5K+ patient annual capacity • Optimal utilization , quality & COS Manufacturing Facility Dedicated to Global Delivery of Commercial and Clinical TIL Cell Therapies COS = cost of sales Philadelphia, PA Manufacturing facility Countries with clinical trial sites Cryopreserved TIL is manufactured in Philadelphia and shipped to commercial and clinical trial sites across North America, Europe, Asia - Pacific and Australia. Philadelphia Los Angeles Canada Europe South Korea Singapore Australia

12 © 2026, Iovance Biotherapeutics, Inc. 12 ~100 ATCs in North America 1,2 1/3 in Community Setting 10K+ ≤ 100 Population 2 1. Not all authorized treatment centers are listed. 2. U.S. Census Bureau, 2024 Annual Estimates. SEER annual estimated death rate from melanoma: 2 deaths per 100K people: https://seer.cancer.gov/ (accessed August 2026) Amtagvi® Authorized Treatment Centers (ATC)

13 © 2026, Iovance Biotherapeutics, Inc. Broad Amtagvi U.S. Market and Geographic Access Data on file as of August 2026. *Plans or policies that cover Amtagvi, including pharmacy benefit managers (PBMs) Abbreviations: NCCN, National Comprehensive Cancer Network Lives covered; majority with private coverage* >250M >80% >75% of patients covered by private payers & Medicare of patients within 100 miles of patients within 200 miles BROAD PRIVATE & PUBLIC PAYER COVERAGE PROXIMITY TO ATCs >95% The Vast Majority of Addressable Patients Have Coverage and Local Access to ATCs COMPREHENSIVE PATIENT SUPPORT PROGRAM ▪ Reimbursement support ▪ Financial assistance ▪ Travel & logistics

14 © 2026, Iovance Biotherapeutics, Inc. Tumor Infiltrating Lymphocytes (TIL): Leading Cell Therapy Platform for Solid Tumors 1. Amtagvi USPI Circulation Infused TIL circulate in the blood Migration to Tumor Recognition Lysis TIL expansion T cells grown to the billions 1 Tumor collection Tumor resected and shipped Individualized therapy One - time therapy made from a patient’s own cells Billions of TIL recognize multiple patient - specific tumor neoantigens One - time infusion Unique mechanism of action

16 © 2026, Iovance Biotherapeutics, Inc. Unprecedented Rate, Depth & Durability of Responses in Frontline Advanced Melanoma • mPFS and mDOR not reached at ~2 years of median follow up (21.7 months) • All response - evaluable patients demonstrated regression of target lesions • Safety consistent with underlying disease and known safety profiles of pembrolizumab, NMA - LD, lifileucel, and IL - 2 • Late AEs consistent with anti - PD - 1 monotherapy, differentiated from ICI combination therapies 1. Thomas et al, ASCO 2024; Data on file as of May 31, 2024. *Unconfirmed CRs, confirmed following data cut. a One patient without a postdose tumor response assessment was not included. b Target lesion lymph node at baseline decreased by 50% is no longer pathological, and thus is shown here as - 100% representing uCR. Abbreviations: CI, confidence interval; CR, complete response; DOR, duration of response; ICI, immune checkpoint inhibitor; M , m edian; ORR, objective response rate; PD, progressive disease; PFS, progression - free survival; PR, partial response; RECIST, Response Evaluation Crite ria in Solid Tumors; SD, stable disease; SOD, sum of diameters; AE, adverse event; IL - 2, interleukin - 2; NMA - LD, nonmyeloablative lymphodepletion Data support rationale for TILVANCE frontline study: 1 65.2% ORR via RECIST v 1.1 30.4% CR 64.7% PFS at 6 & 12 months Best Percentage Change from Baseline in Target Lesion SOD Time to Response and Time of Efficacy Assessment for Confirmed Responders (PR or Better)

17 © 2026, Iovance Biotherapeutics, Inc. Option to crossover to lifileucel after BIRC - confirmed PD 1:1 Randomization TILVANCE - 301 Global Phase 3 and Confirmatory Trial *Pembrolizumab in both arms is started at the same time after randomization. Abbreviations: BIRC, blinded independent review committee; ORR, objective response rate; PD, progressive disease; PD - 1, program med cell death protein - 1; PFS, progression free survival Arm A: lifileucel plus pembrolizumab* Long - term follow up Patient Population Unresectable or metastatic melanoma; no prior therapy for metastatic disease N=670 80 + sites in U.S., Canada, Europe, APAC Arm B: pembrolizumab alone* Study Design with FDA Agreement • Dual primary endpoints: ORR & PFS • Interim analysis on ORR • Final analysis on PFS • Registrational for frontline melanoma • Confirmatory for Amtagvi® full approval in post - anti - PD - 1 melanoma • Enrollment on track with internal projections Randomized, Multicenter Study with Optional Crossover to Lifileucel (NCT05727904)

18 © 2026, Iovance Biotherapeutics, Inc. 1M+ Global Annual Deaths 1 Significant Unmet Need in 2L Nonsquamous NSCLC – Limited durability with SOC Chemo (Docetaxel) 2 5.6 mo mDOR 12.3 mo OS 12.8% ORR >90K Annual Deaths 1 1. Data on file as of August 2026, includes targeted patient population (nonsquamous advanced NSCLC) in potential future comm erc ial markets. 2. Ahn MJ et al. J Clin Onc 2024;43:260 - 272. Abbreviations: APAC, Asia Pacific; mDOR, median duration of response; mo , month; NSCLC, non - small - cell lung cancer; ORR, objective response rate; OS, overall survival; SOC, standard of care >150K Annual Deaths 1 >75K Annual Deaths 1 TIL Experience is Growing at Leading Cancer Centers across North America, Europe & APAC Global NSCLC Commercial Opportunity ~7X Current Melanoma Opportunity 1

19 © 2026, Iovance Biotherapeutics, Inc. IOV - LUN - 202 Registrational Trial Design Phase 2 Multicenter Study of Lifileucel in Post - Anti - PD - 1 NSCLC (NCT04614103) Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; IRC, independent review committee; NSCLC, non - small cell lung ca ncer; ORR, objective response rate; TPS, tumor proportion score Iovance TIL Therapy Lifileucel in NSCLC IOV - LUN - 202 is designed to enroll patients with advanced NSCLC post anti - PD - 1 treatment Endpoints • Primary: ORR per RECIST v1.1 by IRC • Secondary: CR rate, DOR, DCR, and PFS; OS; s afety and tolerability Patient Population Unresectable or metastatic NSCLC with progression on or after prior anti - PD - 1 treatment and chemotherapy 70+ sites in U.S., Canada, Europe, APAC Cohort 1: < 1% or unknown TPS Cohort 2: ≥ 1% TPS Registrational Cohorts

20 © 2026, Iovance Biotherapeutics, Inc. FDA Fast Track Designation in Second - Line Nonsquamous mNSCLC 1. Interim data cut as of October 10, 2025 of patients with nonsquamous NSCLC with minimum cell dose based on FDA feedback in me lan oma. Patients progressed on or after chemotherapy and anti - PD - 1 therapy for mNSCLC without EGFR, ROS1 or ALK genomic mutations and received at least one line of FDA - approved targeted therapy if indicated by other actionable tumor mutatio ns. 2. Time to response, time on assessment for confirmed responders (PR or better). A bar is presented for each patient starting from date of lifileucel infusion up to date of new anti - cancer therapy, end of assessment, death, or data cutoff date, whichever occurs earlier. *Patient 23 in ongoing follow up to confirm PR. Abbreviations: CR, complete response; mNSCLC, metastatic non - small cell lung cancer; ORR, objective response rate; PD, progressi ve disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; uPR , unconfirmed partial response One - Time Therapy with Unprecedented Durability and Potential Best - in - Class Clinical Profile 1 25.6% ORR (n=39; RECIST v1.1) mDOR Not Reached (Median follow up: 25.4 months) Patients Time (months) Since Lifileucel Infusion % Change From Baseline Durability of Response 2 Patients Best Percentage Change from Baseline in Target Lesion(s)

21 © 2026, Iovance Biotherapeutics, Inc. Cohort 3A Results Support Adding TIL Therapy to Frontline NSCLC 1 % Change from Baseline Time (Months) Since TIL Infusion PD - L1 Negative, EGFR WT Subgroup has a High Unmet Need 2 Best Percentage Change from Baseline in Target Lesion SOD 64.3% ORR EGFR WT Time to Response for Confirmed Responders (PR or Better, EGFR WT Patients) mDOR not reached (median follow up 26.5 months) • Safety consistent with Iovance TIL combination studies • Supports adding TIL therapy to pembrolizumab plus chemotherapy for frontline NSCLC 1. Creelan et al, SITC 2024 2 . KEYTRUDA USPI; OPDIVO USPI *PR response based on target lesion reduction of 100% with the persistence of nontarget lesions. Abbreviations: CR, complete response; EGFR, epidermal growth factor receptor; ICI, immune checkpoint inhibitor; NSCLC, non - small - cell lung cancer; ORR, objective response rate; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; SOD, sum of diameter; TPS, tumor proportion score; WT, wild - type 54.5% ORR EGFR WT PD - L1 Negative by RECIST v1.1 Anti - PD - 1 ORR Benchmarks 2 27% (TPS ≥ 1%); 39 - 45% (TPS ≥ 50%) Treatment - naïve (mono) 18 - 20% Post - chemotherapy (mono) 48 - 58% Frontline (anti - PD - 1 + chemo) 2 Patients 60 40 20 0 – 20 – 40 – 60 – 80 – 100 a 3A - 03 3A - 16 3A - 08 3A - 22 3A - 15 3A - 09 3A - 04 3A - 02 3A - PD - L1 TPS <1 <1 <1 <1 ≥ 50 <1 <1 <1 <1 3A - 10 ≥ 50 3A - 17 ≥ 50 3A - 11 <1 3A - 13 <1 8 0 10 0 PD SD PR CR

22 © 2026, Iovance Biotherapeutics, Inc. 1. CancerMPact Patient Metrics for US Soft Tissue Sarcoma (accessed February 2026); 2. Zhou et al. BMC Public Health 2025; 3. CancerMPact Treatment Architecture for Sarcoma for the US & EU5 (May 2025) to inform treatment rates in the US and EU5. 4. Parikh RC, et al. Cancer. 2018. 5. Italiano A, et al. Ann Oncol. 2012; 6. Jones RL et al. Ann Oncol. 2023. Abbreviations: 2L, second line; DDLPS, dedifferentiated liposarcoma; DCR, disease control rate; ICI, immune checkpoint inhibitor; ORR, objective response rat e; RECIST, Response Evaluation Criteria in Solid Tumors; SOD, sum of diameter (in millimeters); UPS, undifferentiated pleomorphic sarcoma Significant Market Opportunity for Advanced Soft Tissue Sarcomas FDA Fast Track Designation in Rare , High Grade , Aggressive Refractory UPS & DDLPS with Very High Unmet Need Deep responses improved over time • All evaluable patients had significant disease burden • Safety consistent with lifileucel in other indications Current 2L SOC has low ORR (<5%) with short durability 4 - 6 • No approved ICI options • Patients concentrated at centers of excellence Phase 2 SARATOGA registrational trial commenced in 2Q 2026 • Targeting expedited pathways for registration • Plan to explore additional high grade soft tissue sarcoma subtypes >3 K >5K U.S. annual cases 1 Patients with advanced disease 3 Europe annual cases 2 >3.5K >8K Patients/yr (US & Europe) 50% ORR via RECIST v1.1 2.33 Mean Prior Lines of Therapy 117 mm Baseline Mean SOD

23 © 2026, Iovance Biotherapeutics, Inc. SARATOGA (IOV - SAR - 201) Registrational Trial Phase 2 Multicenter Study of Lifileucel in Advanced Soft Tissue Sarcomas (NCT07741877) Abbreviations: CR, complete response; DCR, disease control rate; DOR, duration of response; IRC, independent review committee; NSCLC, non - small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression free survival; RECIST, Response Evaluation Criteria in Solid Tumors Endpoints Primary : ORR per RECIST v1.1 by IRC Secondary : CR rate, DOR, DCR, PFS, OS, safety and tolerability Patient Population Patients with undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who have received 1 - 3 prior systemic treatments Cohort 1: UPS Cohort 2: DDLPS

24 © 2026, Iovance Biotherapeutics, Inc. 1. National Cancer Institute Surveillance, Epidemiology and End Results (SEER) Program. 2026 Estimates. https://seer.cancer.gov (accessed June 2026 ); 2. World Health Organization International Agency for Research on Cancer (IARC). GLOBOCAN 2022; 3. NCCN Guidelines Version 2.2024 Endometrial Carcinoma; 4. Kang et al, Nature Portfolio, Scientific Reports, 2022; 5. Makker V, et al. N Engl J Med. 2022; 6. McMeekin S, et al. Gynecol Oncol. 2015. Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; pMMR , proficient DNA mismatch repair; dMMR , deficient DNA mismatch repair; SOC, standard of care; TMB - H, tumor mutational burden high; ORR, objective response rate Strong Initial Data for Serous Advanced Endometrial Cancer Biomarker Based Approach in Difficult to Treat Subtype with Very High Unmet Need in 2L+ FDA engagement on expedited pathway planned No standard of care for 2L+ post - anti - PD - 1 • Anti - PD - (L)1 moving into frontline setting, limited data on treatments after anti - PD - (L)1 3 • Mono - chemotherapy after front - line chemo doublet: ~15% ORR 5,6 • Targeted therapies available only to small subgroups ~13K ~90K US annual endometrial cancer deaths 1 5 - yr survival ( distant metastases ) 1 Global deaths 2 19.5% Endometrial Cancer Biomarkers 4 pMMR : 73% dMMR : 27% >40% of Endometrial Cancer Deaths are Serous 40% Confirmed ORR via RECIST v1.1 100% DCR via RECIST v1.1 2 Median Prior Lines of Therapy First 5 evaluable patients all mismatch repair proficient and progressed on prior chemotherapy and checkpoint inhibitor therapy

25 © 2026, Iovance Biotherapeutics, Inc. pMMR Subgroup* dMMR Subgroup* Endpoints • Primary : ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability IOV - END - 201 Phase 2 Proof of Concept Study Endometrial Cancer Patient Population Recurrent, metastatic or primary unresectable disease after chemo and anti - PD - 1 therapy ≤ 3 lines of prior systemic therapy with ≤ 1 line of chemotherapy *Proof of concept cohorts, enrollment complete **Planned Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; CR, complete response; dMMR , mismatch repair deficient; pMMR , mismatch repair proficient; DCR, disease control rate; DOR, duration of response; ORR, objective response rate; OS, overall survival; PFS, progression free survival Proof - of - Concept Trial in Patients with Mismatch Repair (MMR) Proficient and Deficient Tumors (NCT06481592) Serous Endometrial Cohort**

27 © 2026, Iovance Biotherapeutics, Inc. 27 © 2026, Iovance Biotherapeutics, Inc. IOV - 4001: PD - 1 Inactivated TIL Therapy 2 T cell PD - 1 PD - 1 inhibits the ability of T cells to fight cancer: T cells, upon encountering cancer cells, produce PD - 1, a checkpoint receptor that is activated by proteins (PD - L1 and PD - L2) found on cancer and other immune cells. 1 PD - L2 PD - L1 PD - 1 TCR pMHCI PD - L2 PD - L1 Tumor cell Antigen - presenting cell 1. Sharpe AH, Pauken KE, Nat Rev Immunol 2018, 18:153 - 167 2. Natarajan A et.al. AACR 2022 3. Licensed from Cellectis 1 IOV - 4001 TCR pMHCI PD - L2 PD - L1 Tumor cell PD - 1 Inactivated T Cells Avoid Checkpoint Signals: PD - 1 is inactivated using TALEN, restoring the ability of TIL cells to kill cancer cells. 2,3 Cognate Antigen Cognate Antigen

28 © 2026, Iovance Biotherapeutics, Inc. Phase 1/2 Open - Label First - in - Human Study: IOV - GM1 - 201 Endpoints • Phase 1: Safety (Complete) • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability Genetically Modified, PD - 1 Inactivated TIL Therapy IOV - 4001 in Previously Treated Metastatic Melanoma and NSCLC (NCT05361174) Cohort 1: Unresectable or metastatic melanoma Post - anti - PD - 1/L1, post - BRAF/MEK inhibitor in patients with BRAF mutations (fully enrolled) Cohort 2: Stage III or IV NSCLC Post - anti - PD - 1/L1 or post targeted therapy and either chemotherapy or anti - PD - 1/L1 Patient Population Adults with unresectable or metastatic melanoma or advanced NSCLC Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; CR, complete response; DCR, disease control rate; DOR, duration of response; NSCLC, non - small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression free survival; RECIST, Response Evaluation Criteria in Solid Tumors

29 © 2026, Iovance Biotherapeutics, Inc. 29 © 2026, Iovance Biotherapeutics, Inc. IOV - 3001: Next Generation IL - 2 for TIL Supportive Regimen 1,2 Phase 1/2 trial enrolling patients Recombinant fusion protein designed to enhance TIL survival and cellular proliferation • A modified copy of the coding sequence for aldesleukin (mdIL - 2) is fused to a humanized monoclonal immunoglobulin (Ig)G1 κ antibody • The mdIL - 2 moiety of IOV - 3001 binds to the IL - 2 - receptor (IL - 2R) with subsequent phosphorylation of signal transducer and activator of transcription 5 (STAT5), resulting in enhanced performance 1. Mitra S, Leonard WJ, Journal of Leukocyte Biology 2018 103(4): 643 - 655 2. Simpson - Abelson M et al, ASCO 2024 Gene Expression: • Survival • Proliferation mdIL - 2 IL - 2R JAK1 P JAK3 STAT5 dimer Cytosol Nucleus P IOV - 3001 IOV - 3001 Heavy chain Light chain IOV - 3001 Modified IL - 2 (mdIL - 2) TIL Antibody Preclinical data suggest a better safety profile and less frequent dosing for IOV - 3001 compared to Proleukin

30 © 2026, Iovance Biotherapeutics, Inc. IOV - 5001: IL - 12 Tethered TIL Therapy 1. Zhang L, et al, Clin Cancer Res 2015;21(10):2278 – 2288; 2. Zhang L, et al, J Immunother Cancer 2020;8:e000210; 3. Kobayashi M, et al, J Exp Med 1989;170:827 – 845; 4. Zeh HJ, et al, J Immunother 1993;14:155 – 61; 5. Tugues S, et al, Cell Death and Differentiation 2015;22:237 – 246; 6. Cao X, et al, Cancer Res 2009;69:8700 – 9; 7. Steding CE, et al, Imm unology 2011;133:221 – 38 • Tethered IL - 12 TIL cells can improve efficacy by remodeling the suppressive TME into an immuno - supportive state – In advanced melanoma patients, an ORR of 63% (n=16) was observed with prior generation IL - 12 secreting TIL product at doses 10 - to 100 - fold lower than conventional TIL products 1 • IL - 12 shows independent clinical efficacy, with safe delivery to the TME being the primary challenge 1,2 • Expression of IL - 12 on IOV - 5001 is induced upon antigen encounter in the TME 1,2 • IOV - 5001’s expressed IL - 12 is tethered to the membrane surface of TIL to avoid release into circulation (shedding) 2 • Inducible IL - 12 expression in the TME and lack of IL - 12 shedding expected to allow increased IOV - 5001 cell doses and improved TIL efficacy in solid tumor cancers Abbreviations: IL - 12, interleukin 12; IND, investigational new drug application; MDSC, myeloid derived suppressor cell; NK, nat ural killer cell; NKT, natural killer T cell; ORR, objective response rate; TME, tumor microenvironment; Treg, regulatory T c ell NK and NK - T cell activation and proliferation 3 CD8 + T cell activation and proliferation 4 CD4 + T cell differentiation to Th1 5 T reg and MDSC downregulation 6,7 30 Direct Action IFN γ Cytosol Nucleus TIL NFAT - TeIL - 12 IL - 12 IL - 12R TCR Antigen © 2026, Iovance Biotherapeutics, Inc. IND - Cleared: Phase 1/2 Basket Trial Enrolling in Solid Tumors Representing 100K+ U.S. Deaths Annually

31 © 2026, Iovance Biotherapeutics, Inc. Phase 1/2 Open - Label First - in - Human Study: IOV - GE1 - 201 Endpoints • Phase 1: Safety • Phase 2 Primary: ORR per RECIST v1.1 by investigator • Secondary : CR rate , DOR, DCR, PFS, OS, safety and tolerability Genetically Engineered, IL - 12 Tethered TIL Therapy IOV - 5001 in Previously Treated Advanced Solid Tumors (NCT07743723) Cohort 1: Stage IV NSCLC without EGFR, ALK, or ROS1 genomic alterations Cohort 2: Unresectable or Stage IV TNBC or ER - low breast cancer Patient Population Adults with previously treated unresectable or metastatic solid tumor cancers Abbreviations: Anti - PD - 1, anti - programmed cell death inhibitor; CR, complete response; CRC, colorectal cancer; DCR, disease cont rol rate; DOR, duration of response; ER, estrogen receptor; HNSCC, head and neck squamous cell carcinoma; NSCLC, non small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression free survival; RECIST, Response Evaluation Criteria in Solid Tumors ; TNBC, triple negative breast cancer Cohort 3: Stage IV CRC Cohort 4: Stage III or IV HNSCC

33 © 2026, Iovance Biotherapeutics, Inc. *The midpoint represents an increase of $55 million, or ~15%, over the previous guidance range of $350 to $370 million. 1. Excludes depreciation and amortization 2. Cash, cash equivalents, short - term investments, and restricted cash as of June 30, 2026 Financial Position & Outlook Cash runway into 2H 2028 Revenue Growth | Margin Improvement | Cost Control Cash position 2 ~$304M 2Q26 Margin 1 56% 2Q26 Revenue >10% Above 2Q26 Guidance ~$99M Full Year 2026 Revenue Guidance $410M — $420M*